These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32576176)

  • 1. Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma.
    Mäkelä R; Arjonen A; Härmä V; Rintanen N; Paasonen L; Paprotka T; Rönsch K; Kuopio T; Kononen J; Rantala JK
    BMC Cancer; 2020 Jun; 20(1):590. PubMed ID: 32576176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.
    Collazo-Lorduy A; Castillo-Martin M; Wang L; Patel V; Iyer G; Jordan E; Al-Ahmadie H; Leonard I; Oh WK; Zhu J; McBride RB; Cordon-Cardo C; Solit DB; Sfakianos JP; Galsky MD
    Eur Urol; 2016 Nov; 70(5):771-775. PubMed ID: 27178450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical analysis of 14 cases of urachal carcinoma].
    Chen ZF; Wang F; Qin ZK; Dai YP; Zhou FJ; Han H; Liu ZW; Yu SL; Li YH; Ye YL
    Ai Zheng; 2008 Sep; 27(9):966-9. PubMed ID: 18799037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report.
    Shelekhova KV; Zhuravlev AS; Krylova DD; Konstantinov AS; Shtan LV; Kheinshtein VA
    Int J Surg Pathol; 2017 Sep; 25(6):563-566. PubMed ID: 28449606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic urachal cancer responding to FOLFOX chemotherapy.
    Tran B; McKendrick J
    Can J Urol; 2010 Apr; 17(2):5120-3. PubMed ID: 20398453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laparoscopic partial cystectomy with en bloc resection of the urachus for urachal adenocarcinoma.
    Hong SH; Kim JC; Hwang TK
    Int J Urol; 2007 Oct; 14(10):963-5. PubMed ID: 17880303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion.
    Han L; Gallan A; Paner GP
    Am J Surg Pathol; 2019 Apr; 43(4):475-479. PubMed ID: 30475253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds.
    Göttlich C; Müller LC; Kunz M; Schmitt F; Walles H; Walles T; Dandekar T; Dandekar G; Nietzer SL
    J Vis Exp; 2016 Apr; (110):e53885. PubMed ID: 27077967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
    BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of urachal carcinoma treated with S-1/CDDP combination chemotherapy].
    Sekita N; Fujimura M; Arai H; Shibata N; Nishikawa R; Sugano I; Mikami K
    Hinyokika Kiyo; 2010 Aug; 56(8):447-51. PubMed ID: 20808064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case series of urachal adenocarcinoma: Imaging features.
    Sah A; Triveni GS; Chandrashekhara SH
    J Cancer Res Ther; 2024 Apr; 20(3):1057-1060. PubMed ID: 39023619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.
    Chang N; Lee HW; Lim JE; Jeong DE; Song HJ; Kim S; Nam DH; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Oncotarget; 2016 Aug; 7(32):51626-51639. PubMed ID: 27438149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer.
    Choi KM; Cho E; Kim E; Shin JH; Kang M; Kim B; Han EH; Chung YH; Kim JY
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):311-318. PubMed ID: 30466782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.
    Ruiz C; Kustermann S; Pietilae E; Vlajnic T; Baschiera B; Arabi L; Lorber T; Oeggerli M; Savic S; Obermann E; Singer T; Rothschild SI; Zippelius A; Roth AB; Bubendorf L
    PLoS One; 2016; 11(8):e0160807. PubMed ID: 27548442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.